Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
暂无分享,去创建一个
Allan H Friedman | R. McLendon | A. Friedman | D. Bigner | H. Friedman | D. Reardon | J. Rich | A. Desjardins | J. Sampson | J. Vredenburgh | Sridharan Gururangan | Roger E McLendon | Darell D Bigner | Jeremy N Rich | David A Reardon | J. Herndon | J. Quinn | S. Gururangan | James J Vredenburgh | Annick Desjardins | James E Herndon | Jennifer A Quinn | Henry S Friedman | John H Sampson | Sara Xiaoyin Jiang | Amy Walker | S. Jiang | A. Walker | Sara Jiang
[1] F. Balis,et al. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. McLendon,et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Felker,et al. Treatment of subcutaneous and intracranial brain tumor xenografts withO6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea , 2004, Cancer Chemotherapy and Pharmacology.
[4] Luca Regli,et al. Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.
[5] M. Dolan,et al. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. , 1995, Progress in nucleic acid research and molecular biology.
[6] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[7] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[8] M. Prados,et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. , 1996, Cancer research.
[9] E. Newlands,et al. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. , 1996, British Journal of Cancer.
[10] B. Kaina,et al. Local intracerebral administration of O6-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma , 2007, Journal of Neuro-Oncology.
[11] E. Newlands,et al. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. , 1996, British Journal of Cancer.
[12] K. Kurisu,et al. O6-Alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications , 2005, Journal of Neuro-Oncology.
[13] A. Friedman,et al. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. , 2004, Neuro-oncology.
[14] R. McLendon,et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. McLendon,et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] H. Eyre,et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Olivi,et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] E. Newlands,et al. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. , 1993, British Journal of Cancer.
[19] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[20] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[21] M. Berger,et al. Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] E. Newlands,et al. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. , 1996, British Journal of Cancer.
[23] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Dolan,et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. , 1995, Cancer research.